DOCSLIB.ORG

Programme Floor Plans Floor Plans Programme

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

For the science and treatment of disorders of the brain PROGRAMME FLOOR PLANS FLOOR PLANS PROGRAMME LEVEL 2 SATURDAY Bleu Bleu Room 235M SUNDAY Room 227M Room 226M Room 225M Room 224M MONDAY Room Grand Grand 221M Amphitheatre Amphitheatre Room Room 241 222M Level 2.5 Level 2.5 Room (mezzanine) (mezzanine) 223M TUESDAY Access to Level 2.5 Access to Level 2.5 Access to Level 3 Exhibition Coee & lunch Access to Coee & lunch Level 3 Welcome reception INDUSTRY Maillot (Saturday 20.00) Coee & lunch Room 211 Room 201 Room 212 Room 213 INFORMATION 1 Room 364 Room 363 Room 362 Room 361 Room 343 Room 342B Room 352AB Speakers’ secretariat (Room 351) Room 341 Access to Poster Level 2 Havane service desk Cash bar Poster podium CME Accreditation Access to Level 2 Poster area ECNP Plaza Bordeaux Room 311 Coee & lunch First Aid Members’ & Faculty lounge Bleu Bleu Room 235M Room 227M Room 226M Room 225M Room 224M Room Grand Grand 221M Amphitheatre Amphitheatre Room Room 241 222M Level 2.5 Level 2.5 Room (mezzanine) (mezzanine) 223M Access to Level 2.5 Access to Level 2.5 Access to Level 3 Exhibition Coee & lunch Access to Coee & lunch Level 3 Welcome reception Maillot (Saturday 20.00) Coee & lunch Room 211 Room 201 Room 212 Room 213 FLOOR PLANS FLOOR PLANS PROGRAMME LEVEL 3 Room 364 SATURDAY Room 363 Room 362 Room 361 SUNDAY Room 343 Room 342B Room 352AB MONDAY Speakers’ secretariat (Room 351) Room 341 TUESDAY Access to Poster Level 2 Havane service desk Cash bar Poster INDUSTRY podium CME Accreditation Access to Level 2 Poster area ECNP Plaza Bordeaux Room 311 INFORMATION Coee & lunch First Aid Members’ & Faculty lounge 2 3 CONTENTS PROGRAMME Floor plans Level 2 1 Level 3 2 Welcome 6 SATURDAY SCIENTIFIC PROGRAMME SOCIAL Types of sessions 8 Poster sessions information 11 SATURDAY MEDIA Sessions 15 AT THE ECNP CONGRESS Keynote session 19 For informational updates SUNDAY SUNDAY Sessions 21 and news flashes during Posters 34 the congress, find us on Facebook and follow us MONDAY Sessions 79 on Twitter. Posters 92 TUESDAY MONDAY @ECNPtweets Sessions 137 Posters 150 INDUSTRY myECNP Introduction 195 List of partners 196 Industry sessions 206 Satellite symposia 209 Expert science exchange 211 TUESDAY Exhibition List of exhibitors 218 Floor plan exhibition 219 INFORMATION Congress information Accreditation 221 For members 223 INDUSTRY For junior scientists 224 Congress committees 226 ECNP Meetings around the congress 229 Info A-Z 230 ECNP general Projects and initiatives 236 Membership 237 INFORMATION Contact 240 5 WELCOME WELCOME PROGRAMME Dear colleagues, SATURDAY When ECNP started over 30 years ago, its focus was The highly popular top paper sessions, introduced last medicines – the science behind them, and how best to use year, will feature again on the programme. In these them in the clinic. Since then, that focus has expanded to sessions, leaders in the field will discuss their selection encompass all brain function as it relates to human brain of the most clinically important and cutting-edge papers, disorders and their treatment. From neuropsychopharma- published in the past 12 months, in their discipline. cology, the ECNP Congress now covers the spectrum of applied and translational neuroscience. We also extend a special welcome to our junior colleagues. We hope this congress will be of added value for junior What has not changed though – and what distinguishes scientists, especially with the new findings symposia SUNDAY the ECNP Congress most of all – is the outstanding quality (S.12 and S.16), career development sessions and our of the science on offer and the commitment to real-world Monday night ‘Science-on-the-rocks’ event. treatments that unites it. For anyone interested in the future of CNS treatments, whether the most innovative Welcome to Paris. We hope you will enjoy the congress! fundamental research or the latest advances in the clinic, Amusez-vous ! there will be no meeting like the ECNP Congress. This reputation for the very best science is one we work MONDAY hard to uphold, and this year is no exception. We are honoured to be able to welcome John Krystal as keynote speaker during the official opening of the congress on Saturday. He will provide us with a fascinating insight Celso Arango Astrid Linthorst into the role of glutamate in psychiatric disease. And we President Chair Scientific Programme have a great line of up of six plenary speakers! Committee This year the congress again covers a widespread range of TUESDAY subjects within neuropsychiatry and applied neuroscience. Speakers will present and discuss forefront research and therapy strategies. Special emphasis will be given to the role of lifestyle and potential interventions in this domain, with symposia, brainstorming and educational update sessions on stress, sleep and exercise (S.19, S.21, S.27, E.06, BS.05, BS.06). A symposium on digital technology in bipolar disorders will open up discussions on the INDUSTRY opportunities and risks of this new approach (S.28). Three poster sessions will provide a further stage for the presenting and discussion of latest data in the field. INFORMATION 6 7 PROGRAMME | TYPES OF SESSIONS PROGRAMME | TYPES OF SESSIONS PROGRAMME In alphabetical order Patient session (ES) A special session dedicated to addressing patient issues Brainstorming sessions (BS) and topics relevant to patient care and families. This year Small, focused interaction sessions organised by ECNP the session will focus on terrorism and the appropriate members on a topic of their choice. The organiser of the care after terrorist attacks. session and a second expert in that specific field of interest SATURDAY will initiate the discussion. Plenary lectures (PL) The plenary lectures are presented by internationally Career development sessions (CD) eminent scientists. Six plenary lectures are scheduled, These practical sessions each feature a leading expert in one of which will be delivered by the 2017 ECNP the field. The expert is specifically invited to share with you Neuropsychopharmacology Award winner, Michel Hamon. his/her wealth of knowledge and experience. The topics are especially interesting for junior scientists, but sessions Poster sessions (P) are open to all participants. Career development sessions For detailed information about the poster sessions, are held daily during the poster sessions. please see the next chapter ‘Poster sessions information’. SUNDAY Industry sessions Rapid-fire poster sessions (RF) Satellite symposia (C) These sessions will give 18 of the highest-scoring poster These scientifically oriented sessions are organised by presenters the chance to present their data in a 5-minute and with educational financial support from industry. presentation. Rapid-fire poster presenters will be selected The programmes have been reviewed for balance and based on the quality of their abstract, and receive this rigour by the Scientific Programme Committee and are extra benefit in addition to their participation in the general accredited for European CME. poster sessions with a poster board. MONDAY Expert science exchange (CE) Symposia (S) The expert science exchange provides the opportunity for Symposia are divided into five tracks: focused, scientifically driven engagement between industry and participants. Each session has six presentations which CT Clinical Treatment track: the latest in therapies can be attended separately. Each presentation has a limited and clinical applications capacity of 80 participants and admittance is given on a CR Clinical Research track: cutting-edge discoveries first-come-first-served basis. The sessions are organised in clinical neuroscience by and with educational financial support from industry. TR Translational Research track: the latest translational TUESDAY and cross-disciplinary research Keynote session (KL) PR Preclinical Research track: break-through research As the centrepiece of the keynote session, the keynote in basic neuroscience lecture features a world-renowned speaker who is ET Educational track: up-to-date insights and practice- especially invited to present on a topic of interest to all oriented education. congress participants. The keynote session will take place The sessions in the educational track focus on a on Saturday 2 September 2017, followed by the welcome continuous dialogue between the participants and the reception. The 2017 keynote lecture will be presented by presenters. Different angles of a subject are discussed INDUSTRY John Krystal, Yale University School of Medicine, USA, and state-of-the-art summaries are provided, with on ‘Targeting glutamate in psychiatric disease’. emphasis on new information relevant for clinical practice. A ‘key pad’ system is used to make the Nomenclature session (NS) sessions more interactive. A lunchtime session on Sunday, specially dedicated to the classification of psychotropic drugs by means of the The symposia are scheduled in six parallel sessions, daily Neuroscience-based Nomenclature. The topic is ‘Why and at 09.00-10.40 and 15.00-16.40 (on Saturday only from how psychotropic nomenclature was changed: presenting 16.50-18.30). In each symposium, four speakers present INFORMATION the NbN app – focus on the paediatric’. on a specific topic. 8 9 PROGRAMME | TYPES OF SESSIONS POSTER SESSIONS INFORMATION PROGRAMME New findings symposia POSTER SESSIONS PROGRAMME Two fixed symposia, one scheduled in the preclinical research track and one in the translational research track. Poster sessions are held Sunday, Monday and Tuesday Eight speakers per symposium are selected from the at 12.15-13.45, in the poster area. The posters are participants at the ECNP Workshop for Junior Scientists in grouped into eight topics. Europe, which is held every year in March SATURDAY in Nice, France. Poster sessions are scheduled during the lunch break to allow ample time for participants to discuss the data Regulatory spotlight session presented. Poster presenters will be at their paper poster A special regulatory dialogue session with the European for further explanation and discussion, and to answer any Medicines Agency (EMA).
Recommended publications
  • Edison Healthcare Insight

    Edison Healthcare Insight

    Edison Healthcare Insight December 2020 Published by Edison Investment Research The Edison healthcare team www.edisongroup.com Maxim Jacobs Dr Nathaniel Calloway Max joined Edison’s healthcare team in December Nathaniel Calloway joined the healthcare team in 2014. Prior to this he worked as a senior analyst at December 2015. Before Edison, he performed Guidepoint Global. Max has also previously worked healthcare investment research for a fund at Bishop as a senior analyst at Ridgemark Capital, a sector Rosen and for Wainscott Capital Partners. Prior to head at Broadfin Capital and as a senior analyst at his role as an analyst he performed molecular Mehta Partners. He is a CFA charter holder. neuroscience research at Cornell Medical School and holds a PhD in chemistry from Cornell. He has published eight scientific papers on topics ranging from physical chemistry to immunology, and he has been recognised as an American Heart Association fellow and an American Chemical Society Medicinal Chemistry fellow. Pooya Hemami Dr John Savin Pooya is a licensed optometrist with over five years John is an analyst working on biotech, pharma, of experience in life sciences equity research. Prior medical device and diagnostics companies. As to joining Edison, he covered the Canadian founder CEO of Physiomics, he devised the healthcare sector as a research analyst at strategy, raised funds and took the company to AIM Desjardins Capital Markets. He holds a doctor of in 2004. At Greig Middleton, John was director in optometry degree from the University of Montreal, charge of the pharma and biotech analyst team and and an MBA (finance concentration) from McGill worked with corporate finance on fund-raising, IPOs University.
  • The Role of the Serotonergic System and the Effects of Antidepressants During Brain Development Examined Using in Vivo Pet Imaging and in Vitro Receptor Binding

    The Role of the Serotonergic System and the Effects of Antidepressants During Brain Development Examined Using in Vivo Pet Imaging and in Vitro Receptor Binding

    From THE DEPARTMENT OF CLINICAL NEUROSCIENCE Karolinska Institutet, Stockholm, Sweden THE ROLE OF THE SEROTONERGIC SYSTEM AND THE EFFECTS OF ANTIDEPRESSANTS DURING BRAIN DEVELOPMENT EXAMINED USING IN VIVO PET IMAGING AND IN VITRO RECEPTOR BINDING Stal Saurav Shrestha Stockholm 2014 Cover Illustration: Voxel-wise analysis of the whole monkey brain using the PET radioligand, [11C]DASB showing persistent serotonin transporter upregulation even after more than 1.5 years of fluoxetine discontinuation. All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Universitetsservice-AB © Stal Saurav Shrestha, 2014 ISBN 978-91-7549-522-4 Serotonergic System and Antidepressants During Brain Development To my family Amaze yourself ! Stal Saurav Shrestha, 2014 The Department of Clinical Neuroscience The role of the serotonergic system and the effects of antidepressants during brain development examined using in vivo PET imaging and in vitro receptor binding AKADEMISK AVHANDLING som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras i CMM föreläsningssalen L8:00, Karolinska Universitetssjukhuset, Solna THESIS FOR DOCTORAL DEGREE (PhD) Stal Saurav Shrestha Date: March 31, 2014 (Monday); Time: 10 AM Venue: Center for Molecular Medicine Lecture Hall Floor 1, Karolinska Hospital, Solna Principal Supervisor: Opponent: Robert B. Innis, MD, PhD Klaus-Peter Lesch, MD, PhD National Institutes of Health University of Würzburg Department of NIMH Department
  • The Effect of the Roots of Empathy Program on the Use of Psychotropic Medications Among Youth in Manitoba

    The Effect of the Roots of Empathy Program on the Use of Psychotropic Medications Among Youth in Manitoba

    The effect of the Roots of Empathy program on the use of psychotropic medications among youth in Manitoba by Lindsey Dahl A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements of the degree of MASTER OF SCIENCE Department of Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine University of Manitoba Winnipeg Copyright © 2017 by Lindsey Dahl Abstract Background: Psychotropic medications prescriptions to youth have increased. Roots of Empathy (ROE) is a social and emotional learning program that may influence the use of psychotropic medication. Methods: Administrative data was analyzed in a matched sample of children who received ROE during 2002/03 to 2012/13. Kaplan-Meier survival curves and Cox proportional hazard models were used to estimate the association between ROE and psychotropic medication dispensations. Results: Few significant differences were observed. Children who received ROE in kindergarten to grade 3 had a lower adjusted hazard for an anxiolytic dispensation. Children who received ROE in grade 7 to 8 had a higher hazard for an antipsychotic dispensation. Males who received the program had an increased hazard for an antipsychotic dispensation. Conclusion: There was no consistent differences in the likelihood of being dispensed a psychotropic medication between children who received ROE and children who did not in Manitoba. ii Acknowledgments I would like to first thank my thesis advisor Dr. Randy Fransoo of the Department of Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine at the University of Manitoba. Right from our initial meeting, Dr.
  • Cairo Alexandria 16-Jul 03:00.37 1 2 AMR MOHAMED

    Cairo Alexandria 16-Jul 03:00.37 1 2 AMR MOHAMED

    2017 UIPM LASER RUN CITY TOUR (LRCT) WORLD RANKING - ELITE DIVISON Updated 16/11/2017 after LRCT: Tbilisi (GEO), 01/04/2017 Sausset Les Pins (FRA), 08/04/2017 Karnal (IND), 09/04/2017 Rostov on Don (RUS), 01/05/2017 Rustavi (GEO), 06/05/2017 Lagos (NGR), 06/05/2017 Kiev (UKR), 14/05/2017 Perpignan (FRA), 14/05/2017 Pretoria (RSA), 20/05/2017 Cairo (EGY), 26/05/2017 Covilha (POR), 03/06/2017 Bath (GBR), 04/06/2017 Alexandria (EGY), 16/06/2017 Pune (IND), 17/06/2017 London (GBR), 18/06/2017 Madiwela Kotte (SRI), 25/06/2017 Alenquer (POR), 25/06/2017 Hull (GBR), 02/07/2017 Singapore (SIN), 30/07/2017 Delhi (IND), 27/08/2017 Mossel Bay (RSA), 02/09/2017 Geelong (AUS), 02/09/2017 Thessaloníki (GRE), 16/09/2017 Amadora (POR), 24/09/2017 Colombo (SRI), 30/09/2017 Division ELITE Age Group U11 Running Sequence 2x400m Gender Female Shooting Distance 5m (2 hands opt) Athlete Best Natio LRCT # UIPM ID School/ Club Name LRCT City Finishing WR Surname First Name n Date Time 1 WALED MOHAMED OSMAN MOHAMED ELGENDY GANA EGY Ahly bank - cairo Alexandria 16-Jul 03:00.37 1 2 AMR MOHAMED ABDELFATTAH MOHAMED SARA EGY Shams club Alexandria 16-Jul 03:01.20 2 3 HAZEM AHMED SAMIR MOHAMED AHMED SAMAHA SHAHD EGY Shams club Alexandria 16-Jul 03:07.50 3 4 MOHAMED SALAH HUSSIEN ELSAYED BASMALA EGY Shams club Alexandria 16-Jul 03:10.39 4 5 ALAA KAMAL ELSAYED GHONEM LAILA EGY Shams club Alexandria 16-Jul 03:11.08 5 6 ABDALLAH MOHAMED ABDALLAH SALAMAH ZINA EGY Shams club Alexandria 16-Jul 03:12.33 6 7 HISHAM ALI MAHMOUD YOUMNA EGY Sherouk Alexandria 16-Jul 03:16.12 7 8
  • List of Registred Drugs in Armenia (01.03.2017-31.03.2017)

    List of Registred Drugs in Armenia (01.03.2017-31.03.2017)

    LIST OF REGISTRED DRUGS IN ARMENIA (01.03.2017-31.03.2017) International nonproprietary name Dose and Registration Term of Legal Status N Trade name Drug form Manufacturer Country ATC1 code License holder (generic) or active packaging number registration for Supply ingredients name Eli Lilly Regional Lilly France S.A.S., Operations GmbH., solution for 100IU/ml, Zone Industrielle, 2 17.03.2017 1 Abasaglar insulin glargine France A10AE04 16535 PoM2 Koelblgasse 8-10, injection 3ml cartridges (5) rue du Colonel Lilly, 17.03.2022 1030, Vienna, 67640 Fegersheim Austria Olainfarm JSC, 5 300mg, Olainfarm JSC, 5 06.03.2017 Rupnicu Str., 2 Adaptol mebicar capsules hard in blister (20/2x10/, Rupnicu Str., Olaine, Latvia N06BX21 16440 PoM 06.03.2022 Olaine, LV-2114, 30/3x10/, 40/4x10/) LV-2114 Latvia Olainfarm JSC, 5 Olainfarm JSC, 5 500mg, 06.03.2017 Rupnicu Str., 3 Adaptol mebicar tablets Rupnicu Str., Olaine, Latvia N06BX21 16441 PoM in blister (20/2x10/) 06.03.2022 Olaine, LV-2114, LV-2114 Latvia 10mg, Pharmstandard- OTCPharm PJSC, fabomotizole in blisters Leksredstva JSC, 27.03.2017 123317, Moscow, 4 Afobazol (fabomotizole tablets (30/1x30/, 60/3x20/, 305022, Kursk, Russia N05BX04 14729/2 PoM 30.07.2020 Testovskaya str., 10, dihydrochloride) 60/2x30/, 90/3x30/, Agregatnaya 2nd str., Russia 120/4x30/) 1a/18 Gedeon Richter 15mg/g, Gedeon Richter PLC, 17.03.2017 PLC, Gyomroi ut 5 Airtal aceclofenac cream 60g aluminium Gyomroi ut 19-21, Hungary M01AB16 16514 OTC3 17.03.2022 19-21, 1103 tube 1103 Budapest Budapest, Hungary 1 Gedeon Richter PLC, Gyomroi ut 19-21, 1103 Budapest - batch releaser, Industrias Gedeon Richter Farmaceuticas powder for oral 100mg, 17.03.2017 PLC, Gyomroi ut 6 Airtal aceclofenac Almirall S.L., Ctra.
  • Glutamate and Microglia Activation As a Driver of Dendritic Apoptosis: a Core Pathophysiological Mechanism to Understand Schizop

    Glutamate and Microglia Activation As a Driver of Dendritic Apoptosis: a Core Pathophysiological Mechanism to Understand Schizop

    Parellada and Gassó Translational Psychiatry (2021) 11:271 https://doi.org/10.1038/s41398-021-01385-9 Translational Psychiatry PERSPECTIVE Open Access Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia Eduard Parellada 1,2,3 and Patricia Gassó 1,2,4 Abstract Schizophrenia disorder remains an unsolved puzzle. However, the integration of recent findings from genetics, molecular biology, neuroimaging, animal models and translational clinical research offers evidence that the synaptic overpruning hypothesis of schizophrenia needs to be reassessed. During a critical period of neurodevelopment and owing to an imbalance of excitatory glutamatergic pyramidal neurons and inhibitory GABAergic interneurons, a regionally-located glutamate storm might occur, triggering excessive dendritic pruning with the activation of local dendritic apoptosis machinery. The apoptotic loss of dendritic spines would be aggravated by microglia activation through a recently described signaling system from complement abnormalities and proteins of the MHC, thus implicating the immune system in schizophrenia. Overpruning of dendritic spines coupled with aberrant synaptic plasticity, an essential function for learning and memory, would lead to brain misconnections and synaptic inefficiency underlying the primary negative symptoms and cognitive deficits of schizophrenia. This driving hypothesis has relevant therapeutic implications, including the importance of pharmacological interventions during
  • Annual Report 2004 Neurobiology R Esearch U

    Annual Report 2004 Neurobiology R Esearch U

    Annual Report 2004 Neurobiology Research U nit Dept. Neurology, Neuroscience Centre Rigshospitalet The H ealth Science Faculty Copenhagen U niversity www.nru.dk F ront page: A 3D reconstruction of a hierarchical clustering. The central blue cluster matches well the spatial location of the cerebral venous vasculature. Liptrot et al., 2004. Preface This annual report provides an overview of the scientific activities that took place within the Neurobiology Research U nit (NRU ) in 2004. Two PhD-theses were defended in 2004: Karen H usted Adams defended her thesis on 5- H T 2A receptor binding measurements in a large healthy control group. H er thesis is the first of many theses to follow from NRU within the field of clinical molecular neuroimaging studies. Kristin Scheuer, MD, defended her thesis on patients with H ereditary Spastic Paraplegia (H SP). She studied cerebral affection in SPG4 linked H SP by employing functional and structural neuroimaging in combination with comprehensive neuropsychological testing. In April, Professor Gitte M. Knudsen was appointed a tenure position as professor at the U niversity of Copenhagen and in June, she replaced Olaf B. Paulson as chairman of NRU . This ‘generation change’ had been carefully planned over several years and consequently the transition went quite smoothly. Professor Olaf B. Paulson remains as professor at NRU and as chairman of the Danish Research Centre for Magnetic Resonance at H vidovre U niversity H ospital. At the Neuroreceptor Mapping Meeting (NRM) that took place in Vancouver, Canada, this summer NRU was selected as a host of NRM in 2006. The preparations are already in full progress (for more information see also www.nrm06.org) and we look very much forward to welcome our colleagues to Copenhagen in July 2006.
  • LIST of REGISTRED DRUGS in ARMENIA (Up to 31.12.2017)

    LIST of REGISTRED DRUGS in ARMENIA (Up to 31.12.2017)

    LIST OF REGISTRED DRUGS IN ARMENIA (Up to 31.12.2017) International nonproprietary Registration Term of Legal status for N Trade name name (generic) or Drug form Dose and packaging Manufacturer Country ATC1 code License holder number registration supply active ingredients name Lek Pharmaceuticals pefloxacin Lek Pharmaceuticals 400mg, 10.03.2015 d.d., Verovskova Str. 1 Abaktal (pefloxacin tablets film-coated d.d., Verovskova Str. Slovenia J01MA03 14308 PoM2 in blister (10/1x10/) 10.03.2020 57, 1526 Ljubljana, mesylate dihydrate) 57, 1526 Ljubljana Slovenia Lilly France S.A.S., Eli Lilly Regional 100IU/ml, Zone Industrielle, 2 17.03.2017 Operations GmbH., 2 Abasaglar insulin glargine solution for injection France A10AE04 16535 PoM 3ml cartridges (5) rue du Colonel Lilly, 17.03.2022 Koelblgasse 8-10, 67640 Fegersheim 1030, Vienna, Austria Help S.A ,10 ambroxol Help S.A. Pedini, Valaoritou str., GR 6mg/ml, 09.03.2016 3 Abrobion (ambroxol syrup Ioanninon, Ioannina, Greece R05CB06 15404 OTC3 144 52, 125ml glass bottle 09.03.2021 hydrochloride) 45500 Metamorphosis, Attika, Greece Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, 100mg/5ml, 39179 Barleben-batch Sandoz 30g powder in 75ml glass powder for oral releaser, Allphamed Pharmaceuticals d.d., bottle and measuring 20.10.2015 4 ACC acetylcysteine solution with orange Pharbil Arzneimittel Germany R05CB01 14947 OTC Verovskova Str. 57, spoon 5ml, 60g powder in 20.10.2020 flavour GmbH Hildebrandstr. 1000 Ljubljana, 150ml glass bottle and 12, 37081 Gottingen, Slovenia measuring spoon 5ml Germany-bulk manufacturer, packager 1 Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, 39179 Barleben - Sandoz batch releaser Pharmaceuticals d.d., 100mg, 21.11.2014 5 ACC 100 acetylcysteine tablets effervescent (Hermes Pharma Germany R05CB01 13967 OTC Verovskova Str.
  • Issn 2522-9273

    Issn 2522-9273

    ISSN 2522-9273 № 1(2)'2017 Економічні горизонти Щоквартальний науковий журнал Засновник: Уманський державний педагогічний Журнал засновано у січні 2015 року. університет імені Павла Тичини Виходить один раз на квартал. Головний редактор Чирва Ольга Григорівна, доктор економічних наук, професор (Умань, Україна) Свідоцтво КВ № 22865-12765ПP від 02.08.2017 р. Заступники головного редактора Бондарук Таїсія Григорівна, доктор економічних ISSN 2522-9273 наук, професор (Київ, Україна) Левченко Олександр Миколайович, доктор Адреса редакції: вул. Садова, 2, к. 314, м. Умань, економічних наук, професор (Кропивницький, Україна) Черкаська обл., 20300 Редакційна колегія Телефон: +38067-948-95-80 Байрамов Ешгін Алі, кандидат економічних наук E-mail: [email protected] (Баку, Азербайджан) Web: http://economic-horizons.udpu.org.ua Білошкурська Наталія Володимирівна, кандидат економічних наук, доцент (Умань, Україна) Бовкун Ольга Анатоліївна, кандидат економічних наук, Основна тематика видання: доцент (Умань, Україна) Економічна теорія та історія економічної думки Богашко Олександр Леонідович, кандидат економічних Міжнародні економічні відносини наук, доцент (Умань, Україна) Економіка та управління національним Бондарук Ігор Сергійович, кандидат економічних наук, доцент (Умань, Україна) господарством Гечбаія Бадрі Нодарович, доктор економіки, Маркетинг, підприємництво, торгівля та асоційований професор (Батумі, Грузія) біржова діяльність Демченко Тетяна Анатоліївна, кандидат економічних Розвиток продуктивних сил і регіональна наук, доцент (Умань,
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
  • Newron Pharmaceuticals FY18 Results

    Newron Pharmaceuticals FY18 Results

    Newron Pharmaceuticals FY18 results Moving towards R&D inflection points Pharma & biotech 14 March 2019 Newron’s FY18 highlights the steady progression of its CNS R&D pipeline. STARS the pivotal Phase II/III (Sarizotan for Rett’s Syndrome) has Price CHF8.29 completed enrolment and data are expected in Q419. Newron is planning Market cap CHF148m to apply for a global filing and approval strategy once data are available. €0.88:CHF; $1.00:CHF; $1.13:€ Evenamide (schizophrenia), developed internally through Newron’s ion Net cash (€m) at 31 December 2018 43.9 channel discovery platform, could enable a paradigm shift in the treatment Shares in issue 17.8m of refractory schizophrenia patients; in Q219 Newron will initiate two pivotal Phase IIb/III trials. We value Newron at CHF714m. Free float 95% Code NWRN Revenue PBT* EPS* DPS P/E Yield Primary exchange SIX Year end (€m) (€m) (€) (€) (x) (%) Secondary exchange N/A 12/17 13.4 (5.3) (0.32) 0.0 N/A N/A 12/18 4.0 (15.0) (0.84) 0.0 N/A N/A Share price performance 12/19e 8.5 (30.2) (1.69) 0.0 N/A N/A 12/20e 21.6 (8.7) (0.49) 0.0 N/A N/A Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. Xadago ramp up required Newron reported €4.0m in Xadago royalties in FY18 (vs €2.9m in FY17). We assume 8–15% royalty rate depending on country, this implies gross sales of c €50m for the period generated in countries launched in Europe and initial US sales.
  • Department of Clinical Physiology, Nuclear Medicine &

    Department of Clinical Physiology, Nuclear Medicine &

    Department of Clinical Physiology, Nuclear Medicine & PET Annual Report 2017 PET 1991 Scanditronix 32 MeV, 1991 GE4096 PET Scanner – – 25 1993 NMR Spectrometer years anniversary 1993 PET Advance Scanner June, 21st 1992-2017 2001 PET/CT Scanner 2005 PET/CT Scanner 2005 Cyclotron 2 The most grateful 2007 HRRT Scanner thank you to 2009 Radiochemistry Synthesizer the John and Birthe Meyer Foundation 2011 PET/MR Scanner 2017 PET/CT Scanner Rigshospitalet · University of Copenhagen Contents Preface ......................................................................................................................................2 Mission and objectives ...............................................................................................................4 Organisation and staff 2017.......................................................................................................6 Highlights 2017 .......................................................................................................................10 Medical secretaries ..................................................................................................................12 The KF Section ........................................................................................................................14 Water damages ........................................................................................................................16 Inauguration of new professor .................................................................................................19